---
schema_version: "secwatch.filing_event.v1"
accession: "0001171843-26-000462"
form_type: "8-K"
ticker: "TEVA"
cik: "0000818686"
company_name: "TEVA PHARMACEUTICAL INDUSTRIES LTD"
filed_at: "2026-01-28T23:59:59+00:00"
generated_at: "2026-05-16T07:14:54.072216+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Teva posts FY 2025 revenue $17.3B (+4% YoY), non-GAAP EPS $2.93, guides FY26 rev $16.4-16.8B

## Summary
- FY 2025 revenues $17.3B (+4% YoY); GAAP diluted EPS $1.21, non-GAAP diluted EPS $2.93.
- Key innovative brands AUSTEDO ($2.26B, +34% YoY), AJOVY ($673M, +30%), UZEDY ($191M, +63%) drove 35% YoY growth.
- Non-GAAP operating income margin 28.4% (vs 26.2% in 2024); free cash flow $2,396M.
- Gross debt reduced to $16.8B, net debt to $13.3B; credit ratings upgraded by three agencies in 2025.
- 2026 outlook: revenues $16.4-16.8B, non-GAAP diluted EPS $2.57-2.77, free cash flow $2.0-2.4B.

## SEC filing metadata
- accession: 0001171843-26-000462
- form_type: 8-K
- ticker: TEVA
- cik: 0000818686
- company_name: TEVA PHARMACEUTICAL INDUSTRIES LTD
- filed_at: 2026-01-28T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/0001171843-26-000462-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/818686/000117184326000462/f8k_012826.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001171843-26-000462
- JSON: https://secwatch.observer/filing/0001171843-26-000462.json
- Plain text: https://secwatch.observer/filing/0001171843-26-000462.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.